• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aditxt, Inc. - Common Stock (NQ:ADTX)

    2.230 +0.080 (+3.72%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 106,421
    Open 2.150
    Bid (Size) 2.210 (5)
    Ask (Size) 2.250 (11)
    Prev. Close 2.150
    Today's Range 2.130 - 2.270
    52wk Range 2.040 - 27,200.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights ADI-100 Developments in Weekly Update Featuring Leadership Team
    Via Investor Brand Network
    Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™
    From Aditxt, Inc.
    Via Business Wire

    Performance

    YTD
    -95.4%
    -95.4%
    1 Month
    -60.0%
    -60.0%
    3 Month
    -91.9%
    -91.9%
    6 Month
    -98.2%
    -98.2%
    1 Year
    -100.0%
    -100.0%

    More News

    Read More
    KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
    Via Business Wire
    KILL Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™
    Via Business Wire
    InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Mayo Clinic’s Dr. Charles Howe in May 2 Update on ADI-100™ Preclinical Study
    Via Investor Brand Network
    InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Gains IRB Approval for Endometriosis Diagnostic Study
    Via Investor Brand Network
    Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025
    From Aditxt, Inc.
    Via Business Wire
    Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements
    From Aditxt, Inc.
    Via Business Wire
    InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance, Hearing Canceled
    Via Investor Brand Network
    Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
    From Aditxt, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Appili CEO in April 4 Update Focused on Infectious Disease Innovation
    Via Investor Brand Network
    Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
    From Aditxt, Inc.
    Via Business Wire
    InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights CaSe Platform Acquisition in Weekly Update Focused on Early Cancer Detection
    Via Investor Brand Network
    Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
    From Aditxt, Inc.
    Via Business Wire
    What's going on in today's session
    Via Chartmill
    These stocks are moving in today's session
    Via Chartmill
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Acquires Patents for DNA Damage Detection in Cancer Prevention
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
    From Aditxt, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    What's going on in today's session
    Via Chartmill
    Discover the top movers in Wednesday's pre-market session.
    Via Chartmill
    Which stocks are moving after the closing bell on Tuesday?
    Via Chartmill

    Frequently Asked Questions

    Is Aditxt, Inc. - Common Stock publicly traded?
    Yes, Aditxt, Inc. - Common Stock is publicly traded.
    What exchange does Aditxt, Inc. - Common Stock trade on?
    Aditxt, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aditxt, Inc. - Common Stock?
    The ticker symbol for Aditxt, Inc. - Common Stock is ADTX on the Nasdaq Stock Market
    What is the current price of Aditxt, Inc. - Common Stock?
    The current price of Aditxt, Inc. - Common Stock is 2.230
    When was Aditxt, Inc. - Common Stock last traded?
    The last trade of Aditxt, Inc. - Common Stock was at 05/02/25 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.